1. Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, Larson SM, Scheinberg DA. Pharmacokinetics and dosimetry of an α-particle emitter antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40:1935–46.
2. Zalutsky MR, Bigner DD. Radioimmunotherpy with α-particle emitting radioimmunoconjugates. Acta Oncol. 1996;35:373–9.
3. Zalutsky MR, Schuster JM, Garg PK, Archer GE, DeWhirst MW, Binger DD. Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Recent Results Cancer Res. 1996;141:101–22.
4. Nikula TK, McDevitt MR, Finn RD, Wu CC, Kozak RW, Garmestani K, Brechbiel MW, Curcio ML, Pippin CG, Tiffany-Jones L, Geerlings MW, Apostolidis C, Molinet R, Gansow OA, Sheinberg DA. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999;40:166–76.
5. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha-particles. 3. Cell inactivation by alpha-particle traversals of the cell-nucleus. Radiat Res. 1991;128:204–9.